IUPHAR 9TH INTERNATIONAL
CONGRESS OF PHARMACOLOGY

LONDON 1984

PROCEEDINGS

IUPHAR 9TH INTERNATIONAL CONGRESS OF PHARMACOLOGY LONDON 1984

Under the Patronage of HRH The Duke of Edinburgh RG KT

Sponsored by
International Union of Pharmacology; British Pharmacological Society;
The Royal Society

PROCEEDINGS

VOLUME 2

EDITORS

Professor Sir William Paton
Professor James Mitchell
Professor Paul Turner

Assistant Editors
Cheryl Padgham
Eileen Ashcroft

© The Macmillan Press Limited 1984

Softcover reprint of the hardcover 1st edition 1984 978-0-333-36888-6

All rights reserved. No reproduction, copy or transmission of this publication may be made without written permission.

No paragraph of this publication may be reproduced, copied or transmitted save with written permission or in accordance with the provisions of the Copyright Act 1956 (as amended).

Any person who does any unauthorised act in relation to this publication may be liable to criminal prosecution and civil claims for damages.

First published 1984

Published by
Scientific & Medical Division
THE MACMILLAN PRESS LTD
Houndmills, Basingstoke, Hampshire RG21 2XS
and London
Companies and representatives
throughout the world

ISBN 978-0-333-37135-0 ISBN 978-1-349-86029-6 (eBook)

DOI 10.1007/978-1-349-86029-6

IUPHAR 9th INTERNATIONAL CONGRESS OF PHARMACOLOGY LONDON 1984

INVITED PROGRAMME

Volume One

Monday 30 July

Invited Lectures

L1	Localisation of functional activity in the central nervous system by metabolic probes	L. Sokoloff
L2	Pharmacological approaches to neuropeptide function – Substance P	L.L. Iversen
L3	Neglect of function and obsession with structure in toxicity testing	G. Zbinden
L4	Receptor localisation in asymmetric cells	A.W. Cuthbert
L5	The Withering Commemoration Lecture	D. Noble

Symposia

S1	Modification and turnover of receptors	1, 3, 5.
S2	Beta-lactam antibiotics with novel nuclei	1–3, 5, 6.
S3	Antiplatelet and antithrombotic drugs	7.
S4	Mechanisms of action of smooth muscle relaxants	1, 3, 4, 6, 8, 9.
S5	Insulin and insulin-like growth factors, receptors and mediators	2.
S6	Tissue selective toxicity	1, 2, 3, 5.

Papers

Tuesday 31 July

Invited Lectures

L6	Molecular pharmacology of sodium channel of mammalian brain	W.A. Catterall
L8	Dopaminergic nerves	C. Bell
L9	The problems of extrapolating laboratory data to man in teratology	R. Jelinek

Symposia

S7	Regulation of adenylate cyclase	2–6.
S8	Antiviral drugs	3–4, 6–9.
S9	Pain mechanisms	1–6.

Papers

Volume Two

S10	Cardiac inotropic agents	1, 5, 8.
S11	Phospholipase A ₂ inhibitors	1, 2, 6, 7, 9.
S12	Repair and promotion in chemical carcinogenesis	

Wednesday 1 August

Invited Lectures

L12	The role of adrenaline in essential hypertension in man	M.J. Brown
L13	Glutathione and tissue toxicity	S. Orrenius

Symposia

S13	Analysis of drug mechanisms by single ion channel recording	<i>Papers</i>
1.
S14	Modern approaches to drug design	1-4.
S15	Novel antihypertensive drugs	1-4, 7.
S16	Peptide effectors and modulators of secretion	1-6.
S17	Amine oxidase enzymes and their inhibition	1-3, 5, 7-8.
S18	Cellular injury caused by free radicals	2-6.

Thursday 2 August

Invited Lectures

L14	Neuropeptide precursors and acetylcholine receptor: molecular structures and gene expression	S. Numa
L15	Cancer chemotherapy: Examples of current progress and future perspectives	R.E. Handschumacher
L16	Receptors for thromboxanes and prostaglandins	R.L. Jones
L17	Activation of calmodulin by metal cations and occupancy of its metal binding sites	W.Y. Cheung

Symposia

S19	Drugs acting through calcium channels	<i>Papers</i>
4, 5, 7, 8.
S20	New strategies in anti-parasitic chemotherapy	1-7.

Volume Three

S21	Endogenous prostanoids in man	2-6.
S22	Leukotrienes and other lipoxygenase products	1-6.
S23	Steroid receptors	2, 3, 5, 7.
S24	Modes of action of antidepressive drugs	1, 3-7.

Friday 3 August

Invited Lectures

L21	Generation of drug resistance by gene amplification	R.T. Schimke

Symposia

S25	GABA receptors	<i>Papers</i>
2-4, 6-8.
S26	Multiple forms of drug metabolising enzymes	1-6.
S27	Salvage of the ischaemic myocardium	1, 5-7.
S28	Peptides as drugs	2-5.
S29	Interleukins and other cytokines	1-3, 5, 7.
S30	Gastrointestinal mucosal protection	2-7.

CONTENTS OF VOLUME TWO

	<i>Page</i>
Symposium 10 Cardiac inotropic agents	
From foxglove to the heart: classification and mode of action of inotropic agents	
T. Godfraind	3
The use of isolated mammalian cardiac myocytes for the study of inotropic mechanisms	
M.R. Mitchell, T. Powell, D.A. Terrar and V.W. Twist	13
Age related changes in cardiac responsiveness to positive inotropic agents	
J.Gy. Papp	21
 Symposium 11 Phospholipase A₂ inhibitors	
Phospholipase A ₂ inhibitors: Introduction: an overview	
C.Y. Lee	31
The active site of phospholipase A ₂	
R. Renetseder, B.W. Dijkstra, K.H. Kalk and J. Drenth	35
Lipomodulin, a naturally occurring phospholipase A ₂ inhibitory protein	
F. Hirata, Y. Notsu, N. Iwata and R. del Carmine	39
Renocortin: A phospholipase A ₂ inhibitory protein induced by anti-inflammatory steroids: pharmacological and biological properties, development of monoclonal antibodies	
B. Rothhut, F. Russo-Marie, M. Cousin and D. Lando	43
Glucocorticoid-induced phospholipase inhibitory proteins	
M.Di Rosa	47
 Wednesday Invited Lectures	
The role of adrenaline in essential hypertension in man	
M.J. Brown, R.C. Causon, V. Barnes, P. Brennan, Greta Barnes, G. Greenberg and W.E. Miall	53
Glutathione and tissue toxicity	
S. Orrenius, H. Thor, G. Bellomo and P. Moldéus	57
 Symposium 13 Analysis of drug mechanisms by single ion channel recording	
An Overview	
D. Colquhoun	69
 Symposium 14 Modern approaches to drug design	
Receptor mapping by means of interaction energy calculations	
H.-D. Höltje, M. Tintelnot and P. Baranowski	75
N.m.r. studies of drug-receptor interactions as an aid to drug design	
G.C.K. Roberts	81
Physiochemical properties in structure-activity analysis	
M.S. Tute	89
Conformational analysis and neuroleptic pharmacophore identification	
J.P. Tollenaere, H.M. Moereels and L.A. Raymaekers	93
 Symposium 15 Novel antihypertensive drugs	
Discovery and clinical evaluation of novel antihypertensive drugs	
J. Koch-Weser	101

	<i>Page</i>
Angiotensin converting enzyme inhibitors in the treatment of hypertension C.I. Johnston	105
Novel antihypertensive drugs: β -adrenoceptors antagonists and drugs with additional properties D.G. McDevitt	111
α -Adrenoceptor agonists and antagonists in the treatment of hypertension J.L. Reid	121
Novel antihypertensive drugs – thoughts for the future R. Lavery	129
 Symposium 16 Peptide effectors and modulators of secretion	
New perspectives on the molecular mechanism of action of peptide secretagogues O.H. Petersen	135
Mechanisms involved in the regulation of calcium metabolism by secretagogues in the exocrine pancreas I. Schulz, H. Streb and E. Bayerdörffer	141
A comparison of the phosphorylation of $M_r = 33k, 21k$ and $25k$ membrane-bound proteins in the rat pancreas, submitted to various secretagogues J. Christophe, M.C. Vandermeers-Piret, J. Rathe, J.P. Dehaye, N.D. Bui-Nguyen, J. Winand and A. Vandermeers	147
The role of inositol phospholipid turnover in the actions of peptide secretagogues R.P. Rubin and P.G. Bradford	157
New perspectives in the identification, distribution and processing of peptide hormones and neurotransmitters: the gastrins G.J. Dockray	163
Co-existence of peptides and classical neurotransmitters in autonomic regulation of blood flow and exocrine secretion J.M. Lundberg, A. Änggård, T. Hökfelt and J. Fahrenkrug	169
 Symposium 17 Amine oxidase enzymes and their inhibition	
Enzymological and pharmacological aspects of monoamine oxidase K.F. Tipton, A.M. O'Carroll and F. Hasan	179
Endogenous substrates and inhibitors of monoamine oxidase M. Sandler, V. Glover and J.D. Elsworth	187
Connections between monoamine oxidase, temperament and disease L. Oreland, L.v. Knorring and D. Schalling	193
The role of monoamine oxidase A in the metabolism and function of noradrenaline and serotonin M.B.H. Youdim, J.P.M. Finberg, D.M. Kuhn and W.A. Wolf	203
<i>In vitro</i> pharmacology of reversible inhibitors of monoamine oxidase B.A. Callingham	211
Some pharmacological and clinical aspects of reversible MAO inhibitors M. Strolin Benedetti	219
 Symposium 18 Cellular injury caused by free radicals	
Free radical metabolites of L-cysteine and glutathione oxidation R.P. Mason, L.S. Harman and C. Mottley	233
Mechanistical studies and prevention of free radical cell injury J.A. Castro	243

	<i>Page</i>
Free radical intermediates and liver cell necrosis J.R. Gillette, S.S. Lau, T.J. Monks and L.R. Pohl	251
The contribution of covalent binding and lipid peroxidation in the pathogenesis of fatty liver by CCl ₄ M.U. Dianzani, U.M. Mariani and G. Poli	259
Models for bleomycin antitumour antibodies: haeminaeridines which bind to DNA, cause oxygen-dependent strand scission, and exhibit anticancer properties J.W. Lown, J. Plenkiewicz, C.W. Ong, A.V. Joshua, J.P. McGovren and L.J. Hanka	265
 Thursday Invited Lectures	
Neuropeptide precursors and acetylcholine receptor: Molecular structures and gene expression S. Numa	273
Cancer chemotherapy: Examples of current progress and future perspectives R.E. Handschumacher	289
Receptors for thromboxane and prostaglandins R.L. Jones, N.H. Wilson, R.A. Armstrong and Y.J. Dong	293
Activation of calmodulin by metal cations and occupancy of its metal- binding sites W.Y. Cheung	303
 Symposium 19 Drugs acting through calcium channels	
Chemical structure and pharmacological activities of Ca ²⁺ channel antagonists D.A. Langa and D.J. Triggle	323
Molecular pharmacology of the calcium channel H. Glossman, D.R. Ferry and A. Goll	329
Vascular smooth muscle and drugs affecting calcium channels G. Haeusler	337
Pharmacology of calcium currents in mammalian central neurones D.A. Brown, R.J. Docherty, J.V. Halliwell, A. Constanti and M. Galvan	343
Site of action of Lambert-Eaton myasthenic syndrome antibodies at mouse nerve terminals D. Wray, C. Prior, J. Newsom-Davies and B. Lang	349
 Symposium 20 New strategies in antiparasitic chemotherapy	
Intermediary metabolism and its regulation in parasitic worms in a strategy for chemotherapy T.E. Mansour	355
Relationships of niridazole metabolism to antiparasitic efficacy and host toxicity L.T. Webster Jr, J.W. Tracy, J.L. Blumer, B.A. Catto and D.L. Sissors	363
The filarial worm as a target for chemotherapy: pharmacological and biological factors influencing drug efficacy R.E. Howells	369
Studies of conditions and agents that stimulate and inhibit the production of caehestin by macrophages M. Kawakami, Y. Ikeda, N. Le Trang, W. Vine and A. Cerami	377

	<i>Page</i>
New approach in design of selectively toxic antimalarials L.W. Scheibel and G.G. Stanton	385
Mechanisms of action of antitrichomonal drugs D.I. Edwards	391
New strategies in antiparasitic chemotherapy: Concluding remarks H. van den Bossche	399
Index	405